VANCOUVER, British Columbia / Nov 21, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:
Live audio webcasts of the presentation may be accessed through the link that will be posted on AbCellera's Investor Relations website. Replays of the webcast will be available through the same links following the presentations.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
Last Trade: | US$4.39 |
Daily Change: | 0.09 2.09 |
Daily Volume: | 4,027,453 |
Market Cap: | US$1.310B |
August 07, 2025 May 30, 2025 May 12, 2025 May 09, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load